25(OH)D3 in patients with ovarian cancer and its correlation with survival

Clinical Biochemistry

Volumn 45, Issue 18, 2012, Pages 1568-1572

  Walentowicz Sadlecka, M ^a   Grabiec, M ^a   Sadlecki, P ^a   Gotowska, M ^b   Walentowicz, P ^a   Krintus, M ^a   Mankowska Cyl, A ^a   Sypniewska, G ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b UNIVERSITY OF TECHNOLOGY AND LIFE SCIENCES   (Poland)

Author keywords

Ovarian cancer; Survival; Vitamin D

Indexed keywords

CALCIFEDIOL;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; VITAMIN BLOOD LEVEL;

ADULT; AGED; CALCIFEDIOL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 84870685232     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.07.110     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Park Y., Lee J.H., Hong D.J., Lee E.Y., Kim H.S. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem 2011, 44(10-11):884-888.
3. Lefkowitz E.S., Garland C.F. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 1994, 23(6):1133-1136.
4. Haussler M.R., Haussler C.A., Bartik L. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev 2008, 66:98-112.
5. Holick M.F. Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol 2008, 3(5):1548-1554.
6. Sutton A., MacDonald P. Vitamin D: more than a "bone-a-fide" hormone. Mol Endocrinol 2003, 17:777-791.
7. Granado-Lorencio F., Olmedilla-Alonso B., Herrero-Barbudo C., Blanco-Navarro I., Blázquez-García S., Pérez-Sacristán B. Simultaneous determination of vitamins A, E and 25-OH-vitamin D: application in clinical assessments. Clin Biochem 2006, 39(2):180-182.
8. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol 2012, 76:315-325.
9. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26:662-687.
10. Moreno J., Krishnan A.V., Feldman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Mol Biol 2005, 97:31-36.
11. Holick M.F. Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets 2011, 12(1):4-18. [Review].
12. Apperly F.L. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941, 1:191-195.
13. Garland C.F., Comstock G.W., Garland F.C., Helsing K.J., Shaw E.K., Gorham E.D. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989, 2:1176-1178.
14. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality. Cancer 1992, 70:2861-2869.
15. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
16. Garland C.F., Garland F.C., Gorham E.D., Lipkin M., Newmark H., Mohr S.B., et al. The role of vitamin D in cancer prevention. Am J Public Health 2006, 96:252-261.
17. Freedman D.M., Dosemeci M., McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med 2002, 59:257-262.
18. Garland C.F., Mohr S.B., Gorham E.D., Grant W.B., Garland F.C. Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am J Prev Med 2006, 31:512-514.
19. Cook L.S., Neilson H.K., Lorenzetti D.L., Lee R.C. A systematic literature review of vitamin D and ovarian cancer. Am J Obstet Gynecol 2010, 203:70.e1-70.e8.
20. Yin L., Grandi N., Raum e., Haug u., Arndt v., Brenner H. Meta-analysis: circulating vitamin D and ovarian cancer risk. Gynecol Oncol 2011, 121(2):369-375.
21. Charzewska J., Chlebna-Sokół D., Chybicka A., Czech-Kowalska J., Dobrzańska A., Helwich E., et al. Prophylaxis of vitamin D deficiency-Polish recommendation 2009. Ginekol Pol 2010, 81(2):149-153.
22. Ali M.M., Vaidya V. Vitamin D and cancer. J Cancer Res Ther 2007, 3(4):225-230.
23. Jiang F., Bao J., Li P., Nicosia S.V., Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the downregulation of telomerase. J Biol Chem 2004, 279:53213-53221.
24. Li P., Li C., Zhao X., Zhang X., Nicosia S.V., Bai W. p27Kip1 stabilization and G1 arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem 2004, 279:25260-25267.
25. Jiang F., Li P., Fornace A.J., Nicosia S.V., Bai W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the Induction of GADD45 via an exonic enhancer. J Biol Chem 2003, 278:48030-48040.
26. Tworoger S.S., Gates M.A., Lee I.M., Buring J.E., Titus-Ernstoff L., Cramer D., et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res 2009, 69(5):1885-1891.
27. Shen Z., Zhang X., Tang J., Kasiappan R., Jinwal U., Li P., et al. The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells. Mol Cell Endocrinol 2011, 338(1-2):58-67.
28. Silvagno F., Poma C.B., Realmuto C., Ravarino N., Ramella A., Santoro N., et al. Analysis of vitamin D receptor expression and clinical correlations in patients with ovarian cancer. Gynecol Oncol 2010, 119(1):121-124.
29. Bakhru A., Mallinger J.B., Buckanovich R.J., Griggs J.J. Casting light on 25-hydroxyvitamin D deficiency in ovarian cancer: a study from the NHANES. Gynecol Oncol 2010, 119(2):314-318.
30. Reinhold U., Schmitz B., Kurbacher C., Nagel W., Schmidt M., Malaisse W.J. Circulating 25-hydroxyvitamin D concentration in German cancer patients. Oncol Rep 2008, 20(6):1539-1543.
31. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357(3):266-281.
32. Pramyothin P., Holick M.F. Vitamin D supplementation: guidelines and evidence for subclinical deficiency. Curr Opin Gastroenterol 2012, 28(2):139-150.
33. Zheng W., Danforth K.N., Tworoger S.S., Goodman M.T., Arslan A.A., Patel A.V., et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010, 172(1):70-80.
34. Toriola A.T., Surcel H.M., Agborsangaya C., Grankvist K., Tuohimaa P., Toniolo P., et al. Serum 25-hydroxyvitamin D and the risk of ovarian cancer. Eur J Cancer 2010, 46(2):364-369.
35. Toriola A.T., Surcel H.M., Calypse A., Grankvist K., Luostarinen T., Lukanova A., et al. Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: a prospective nested case-control study. Eur J Cancer 2010, 46(15):2799-2805.
36. Tworoger S.S., Lee I.M., Buring J.E., Rosner B., Hollis B.W., Hankinson S.E. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(4):783-788.
37. Arslan A.A., Clendenen T.V., Koenig K.L., Hultdin J., Enquist K., Agren A., et al. Circulating vitamin D and risk of epithelial ovarian cancer. J Oncol 2009, 2009:672492. 10.1155/2009/672492.